AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Argenx: HC Wainwright raises Buy rating, PT to $774 from $720.
ByAinvest
Friday, Aug 1, 2025 6:32 am ET1min read
Argenx: HC Wainwright raises Buy rating, PT to $774 from $720.
Title: Argenx: HC Wainwright Raises Buy Rating, Target Price to $774July 02, 2025 — In a significant move for Argenx SE (NASDAQ:ARGX), H.C. Wainwright has upgraded the biotech company's stock to a Buy rating and raised the price target to $774 from $720. This update comes amidst strong progress in Argenx's neuromuscular treatment pipeline and positive second-quarter financial results [1].
Douglas Tsao, an analyst at H.C. Wainwright, cited the company's advancements in the ARGX-119 molecule, which has entered a registrational trial for congenital myasthenic syndromes (CMS). The Phase 1b results demonstrated promising safety and efficacy, boosting investor confidence. ARGX-119 is the third molecule from Argenx to reach late-stage clinical development, further solidifying the company's position in the biotech sector [1].
Additionally, Argenx reported robust second-quarter financials, with Vyvgart revenues reaching $949 million, representing a 20% quarter-over-quarter growth. This performance exceeded both BofA Securities' estimates and consensus expectations. The company's strong global demand growth and the launch of its pre-filled syringe option for at-home dosing contributed to the impressive results [2].
The upgrade reflects the positive outlook on Argenx's pipeline and financial performance. The company's strong balance sheet and profitability metrics also contribute to its appeal among investors. Despite the FDA's evaluation of potential risks associated with Vyvgart Hytrulo, Argenx continues to make strides in its treatment offerings, with the ARGX-119 molecule being a key driver of growth.
References
[1] https://finance.yahoo.com/news/h-c-wainwright-reaffirms-buy-042135381.html
[2] https://za.investing.com/news/analyst-ratings/bofa-securities-raises-argenx-stock-price-target-to-880-on-strong-vyvgart-sales-93CH-3814719
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet